The Quantellect read.As of Nov 19, 2026, 10 active firms cover Medpace Holdings Inc: 2 rate it Buy or better, 8 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets span $492.00 to $700.00, a moderate spread. The average target of $614.44 sits 5% below the current $646.95. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $4.66 next quarter toward $19.85 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 active firms
Neutral
Strong Buy00%
Buy220%
Neutral880%
Sell00%
Strong Sell00%
Based on 10 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$614.44
-5.0% downside
Average target across 9 active firms as of Nov 19, 2026 vs $646.95 current
Highest Target$700.00
Average Target$614.44
Lowest Target$492.00
Detailed analyst forecasts for MEDP
Showing 1–9 of 9 named analysts shown · 10 active firms in the rating projection
As of Nov 19, 2026, 2 of 10 active firms rate MEDP a Buy (8 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
MEDP EPS & revenue forecast
EPS · NEXT QUARTER
$4.66
Range $4.50 – $4.91 · 7 analysts · +9% YoY
Next period, 7 analysts expect Medpace Holdings Inc to earn $4.66 a share (range $4.50 – $4.91), versus $4.28 a year earlier. Full-year consensus is $18.36, growing to $19.85 the year after.
REVENUE · NEXT QUARTER
$726.9M
Range $713.7M – $742.2M · 7 analysts · +3% YoY
Revenue is expected to reach $726.9M (range $713.7M – $742.2M), +2.9% year-over-year. Full-year consensus is $2.8B, rising to $3.0B next year.
Top analysts covering Medpace Holdings Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MEDP.
#1
EC
Eric Coldwell
Baird · Rank #127
Neutral
$624.00-3.5% to target
Overall win rate
37%
+ Follow
#2
Kevin Caliendo
UBS · Rank #165
Neutral
$673.00+4.0% to target
Overall win rate
42%
+ Follow
#3
Luke Sergott
Barclays · Rank #267
Neutral
$625.00-3.4% to target
Overall win rate
43%
+ Follow
#4
RH
Ryan Halsted
RBC Capital
Buy
$692.00+7.0% to target
Coverage
—
+ Follow
#5
Jailendra Singh
Truist Securities
Neutral
$633.00-2.2% to target
Coverage
—
+ Follow
MEDP stock forecast FAQ
What is MEDP's average 12-month price target?+
The 9 active firms with a live target average $614.44 for Medpace Holdings Inc over the next 12 months, ranging from a $700.00 high to a $492.00 low, as of Nov 19, 2026.
Is MEDP stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 10 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 8 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for MEDP?+
The Street-high target is $700.00 (Mizuho), and the Street-low is $492.00 (TD Cowen). The average of all 9 active-firm targets is $614.44.
How many active Wall Street firms cover MEDP?+
10 active firms have a recognized rating on Medpace Holdings Inc as of Nov 19, 2026, and 9 active firms carry a live 12-month price target.
Who is the most accurate analyst covering MEDP?+
Among analysts who currently cover MEDP, Eric Coldwell of Baird has the strongest overall Quantellect track record (Rank #127). Their current call is Neutral with a $624.00 target.
What is Medpace Holdings Inc's projected EPS for next quarter?+
The consensus estimate is $4.66 per share (range $4.50 – $4.91) across 7 analysts. Full-year EPS is projected at $18.36, rising to $19.85 the following year.
How much revenue is Medpace Holdings Inc expected to report next quarter?+
Consensus revenue is $726.9M (range $713.7M – $742.2M). Full-year revenue is projected at $2.8B, growing to $3.0B next year.
Have analysts been upgrading or downgrading MEDP lately?+
As of Nov 19, 2026, 2 of 10 active firms rate MEDP a Buy (8 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MEDP calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.